249 results on '"Tsuboi, Akihiro"'
Search Results
2. Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs
3. An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia
4. Maintenance of WT1 expression in tumor cells is associated with a good prognosis in malignant glioma patients treated with WT1 peptide vaccine immunotherapy
5. Identification of mouse helper epitopes for WT1-specific CD4+ T cells
6. Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides
7. Cellular and Humoral Immune Responses Induced by an HLA Class I–restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer
8. A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma
9. Induction of WT1 (Wilms' Tumor Gene)-Specific Cytotoxic T Lymphocytes by WT1 Peptide Vaccine and the Resultant Cancer Regression
10. Enhanced immune reaction resulting from co-vaccination of WT1 helper peptide assessed on PET-CT
11. The activated conformation of integrin [beta]7 is a novel multiple myeloma-specific target for CAR T cell therapy
12. Immune adjuvant therapy using Bacillus Calmette–Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: A phase 1 study of safety and immunogenicity assessments
13. Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide
14. Two distinct effector memory cell populations of WT1 (Wilms’ tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients
15. Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response
16. Feasibility of Cancer Immunotherapy with WT1 Peptide Vaccination for Solid and Hematological Malignancies in Children
17. WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1.
18. Functional human Th17 clones with WT1-specific helper activity
19. WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial
20. WT1 peptide vaccine for the treatment of cancer
21. Prognostic value of WT1 protein expression level and MIB-1 staining index as predictor of response to WT1 immunotherapy in glioblastoma patients
22. Vaccination strategies to improve outcome of hematopoietic stem cell transplant in leukemia patients: early evidence and future prospects
23. T Cell-Intrinsic Vitamin A Metabolism and Its Signaling Are Targets for Memory T Cell-Based Cancer Immunotherapy.
24. Wilms Tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma
25. Clinical and Immunologic Responses to Very Low-Dose Vaccination with WT1 Peptide (5 µg/Body) in a Patient with Chronic Myelomonocytic Leukemia
26. WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone
27. Monitoring Minimal Residual Disease in Leukemia Using Real-time Quantitative Polymerase Chain Reaction for Wilms Tumor Gene (WT1)
28. The lck Promoter-Driven Expression of the Wilms Tumor Gene WT1 Blocks Intrathymic Differentiation of T-Lineage Cells
29. Wilms tumor gene peptide-based immunotherapy for patients with overt Leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis
30. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues
31. AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1
32. Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain.
33. Cytotoxic T-Lymphocyte Responses Elicited to Wilms' Tumor Gene WT1 Product by DNA Vaccination
34. Biased usage of T cell receptor β-chain variable region genes of Wilmsʼ tumor gene (WT1)-specific CD8+ T cells in patients with solid tumors and healthy donors
35. CD48 as a novel molecular target for antibody therapy in multiple myeloma
36. WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient
37. Sensitive immunohistochemical detection of WT1 protein in tumors with anti-WT1 antibody against WT1 235 peptide
38. Effects of Concomitant Temozolomide and Radiation Therapies on WT1-specific T-cells in Malignant Glioma
39. High frequencies of less differentiated and more proliferative WT1-specific CD8+ T cells in bone marrow in tumor-bearing patients: An important role of bone marrow as a secondary lymphoid organ
40. Biased usage of BV gene families of T-cell receptors of WT1 (Wilmsʼ tumor gene)-specific CD8+ T cells in patients with myeloid malignancies
41. WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factor
42. Identification of mouse helper epitopes for WT1-specific CD4+ T cells.
43. A WT1 protein-derived, naturally processed 16-mer peptide, WT1332, is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4+ T cells
44. Identification of a WT1 protein-derived peptide, WT1187, as a HLA-A*0206-restricted, WT1-specific CTL epitope
45. Wilmsʼ tumor gene WT1 17AA(–)/KTS(–) isoform induces morphological changes and promotes cell migration and invasion in vitro
46. A Phase I/II Trial of a WT1 (Wilmsʼ Tumor Gene) Peptide Vaccine in Patients with Solid Malignancy: Safety Assessment Based on the Phase I Data
47. Absence of Mutations in the Wilmsʼ Tumor Gene WT1 in Primary Breast Cancer
48. Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells
49. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia
50. The effect on the proliferation and apoptosis of alloreactive T cells of cell dose in a murine MHC-mismatched hematopoietic cell transplantation model
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.